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Peak cell densities in fed-batch cultures of mammalian cells can be limited by the depletion of nutrients or 
accumulation of inhibitors.  Since addition of nutrients is relatively straight forward, inevitably it is growth inhibitor 
buildup, combined with the practical limits of feed volume addition and the problem of amino acid counter ion 
and miscellaneous osmolyte accumulation, that serve to limit productivity in the industry standard fed-batch 
bioreactor.  To break these barriers we have begun to investigate mixed modes of bioreactor operation, some 
using novel methods for cell-controlled perfusion, which can substantially reduce the volumes of perfusion 
medium required, suppress lactic acid formation, shorten the time to reach peak cell densities, and reduce the 
complications associated with cell retention devices.  Our methods of high-intensity perfusion and mixed mode 
bioreactor operation are also more compatible with the move to continuous downstream processing as the 
stream delivered is more concentrated and provides a more continuous daily mass of product to allow for 
reduced affinity chromatography scale.   
 
The techniques we will describe significantly increase viable cell densities and have achieved volumetric 
productivities of 1.0-1.5 grams/L/day (nearly 4X the optimized fed-batch culture in one case) for several 
moderate specific productivity cell lines, while using very modest medium volumes, highly concentrated 
perfusion media, comparatively simple bioreactor operations, and a batch length that fits in a standard fed-batch 
window.  Methods of operation and experimental results obtained at the pilot (100 liter) scale when coordinating 
these hybrid continuous cultures with a continuous downstream process will also be discussed.   
 
 
 
